Navigation Links
U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis

Survey shows hospital physicians, pulmonary and critical care clinicians,

and researchers also concerned about overuse of antibiotics

DURHAM, N.C., July 24 /PRNewswire/ -- bioMerieux recently conducted two surveys, fielded during conferences of the American Thoracic Society and Society of Hospital Medicine, that show how hospitalists, pulmonary and critical care physicians, and researchers are unanimous in their view that new methods and technologies are needed to quickly diagnose and combat severe bacterial sepsis in U.S. hospitals.

Sepsis, a usually fatal medical condition generally caused by the body's response to a severe infection of the blood and/or tissues, affects between 5 and 10 percent of all hospital patients, leading to an increase of about $5 billion in U.S. healthcare costs annually.

bioMerieux's 20-minute test to detect levels of procalcitonin (PCT) -- a telltale sign of systemic bacterial infection -- recently received 510(k) clearance from the U.S. Food and Drug Administration to assess the risk of progression to severe sepsis and septic shock. PCT tests have been used in Europe for years. Nearly all survey respondents said such a test would represent a "dramatic improvement" to the current methods of diagnosis and care for sepsis and suspected sepsis.

Because symptoms of sepsis can be vague and overlap with other diseases, there is no gold standard for diagnosis -- current methods of detection are slow and inaccurate. Of the pulmonary and critical care specialists surveyed, 69 percent viewed overlapping symptoms as the most difficult aspect of diagnosing sepsis. In fact, most clinicians reported starting empiric therapy -- prescribing an antibiotic treatment immediately before an accurate and firm diagnosis is determined -- because the risk of not treating suspected bacterial sepsis is too dangerous. However, according to the surveys, nearly all participating hospitalists and pulmonary and critical care specialists indicated that antibiotic resistance stemming from antibiotic misuse is a primary concern as it may have an increasing effect on the development of Superbugs.

"For decades, advancement of the diagnosis of sepsis has been limited, as doctors continue to rely on clinical clues and symptoms," said Dr. Charles B. Cairns, Professor & Chair, Department of Emergency Medicine, UNC School of Medicine. "Yet it has been shown that early treatment can be life saving. Given the need for timely treatment, antibiotics are frequently prescribed even before bacterial infection is confirmed. This could increase the development of antibiotic-resistant bacterial strains. Healthcare professionals need new tools, like PCT, to rapidly and accurately diagnosis sepsis and severe infections in order to better tailor the use of antibiotics."

Marking a significant shift in the care of sepsis patients, 73 percent of hospitalists indicated that they now play the primary role in managing patients with suspected sepsis, while 83 percent of pulmonary and critical care specialists indicated the same. Of those surveyed, all were nearly unanimous in their desire for a rapid test that would help confirm the cause of suspected sepsis.

Of the hospitalists surveyed, the vast majority was unaware that circulating PCT levels are very sensitive to the severity of bacterial infection and closely track with the severity of that infection(1). PCT, the prohormone of calcitonin, can be produced by numerous cell types and organs after proinflammatory stimulation, especially when caused by bacterial infection. This makes PCT an ideal indicator of systemic bacterial infection and sepsis. When provided information about a new PCT test from bioMerieux, over half of hospitalists said a 20-minute biomarker test that could help with the diagnosis of a clinically relevant bacterial infection and/or sepsis would make a dramatic improvement in patient care and improve antibiotic stewardship.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for 45 years, bioMerieux is present in more than 150 countries through 38 subsidiaries and a large network of distributors. In 2007, revenues reached euro 1.063 billion with 84 percent of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at or

(1) Muller B, Becker KL, Schachinger H, Rickenbacher, PR, Huber PR, Zimmerli W, Ritz R. Calcitonin precursers are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28:977-983.

SOURCE bioMerieux
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
2. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
3. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
4. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
5. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
6. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
7. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
8. U-M research: New plastic is strong as steel, transparent
9. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
10. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... International ... and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. ... 2015, where ISPE hosted the largest number of attendees in more than a ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... -- SHPG ) announced today that Jeff Poulton ... th Annual Healthcare Conference in New York City ... EST (1:30 p.m. GMT). --> SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
Breaking Biology News(10 mins):